Neonc Technologies (NASDAQ:NTHI) CEO Thomas Chen Buys 5,556 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Thomas Chen bought 5,556 shares of the company’s stock in a transaction on Friday, September 11th. The shares were acquired at an average price of $3.60 per share, with a total value of $20,001.60. Following the transaction, the chief executive officer directly owned 19,261 shares in the company, valued at approximately $69,339.60. The trade was a 40.54% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Neonc Technologies Price Performance

NTHI stock opened at $3.31 on Wednesday. The business’s fifty day moving average is $4.04 and its 200-day moving average is $5.27. Neonc Technologies Holdings, Inc. has a twelve month low of $3.01 and a twelve month high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Hedge Funds Weigh In On Neonc Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE acquired a new position in Neonc Technologies during the 2nd quarter worth approximately $1,017,000. BlackRock Inc. acquired a new stake in shares of Neonc Technologies in the second quarter valued at approximately $815,000. Westmount Partners LLC lifted its position in shares of Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new stake in shares of Neonc Technologies in the second quarter worth $126,000.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings upgraded Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Alliance Global Partners began coverage on shares of Neonc Technologies in a research report on Tuesday, May 19th. They issued a “buy” rating and a $13.00 price target on the stock. Wall Street Zen lowered shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research restated a “buy” rating and set a $15.00 price objective on shares of Neonc Technologies in a report on Tuesday, September 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $16.00.

Neonc Technologies News Roundup

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.